Cited by 21Mangiferin and Mango ExtractsNanoparticle-Based Drug DeliveryPharmacology and Nanomedicine Research

Nanotechnology-Based Drug Delivery Approaches of Mangiferin: Promises, Reality and Challenges in Cancer Chemotherapy

Open access
Sarfraz, Muhammad, Khan, Abida, Batiha, Gaber El-Saber, Akhtar, Muhammad Furqan, Saleem, Ammara, Ajiboye, Basiru Olaitan, Kamal, Mehnaz, Ali, Abuzer +4 more·2023·Cancers

Abstract

Mangiferin (MGF), a xanthone derived from Mangifera indica L., initially employed as a nutraceutical, is now being explored extensively for its anticancer potential. Scientists across the globe have explored this bioactive for managing a variety of cancers using validated in vitro and in vivo models. The in vitro anticancer potential of this biomolecule on well-established breast cancer cell lines such as MDA-MB-23, BEAS-2B cells and MCF-7 is closer to many approved synthetic anticancer agents. However, the solubility and bioavailability of this xanthone are the main challenges, and its oral bioavailability is reported to be less than 2%, and its aqueous solubility is also 0.111 mg/mL. Nano-drug delivery systems have attempted to deliver the drugs at the desired site at a desired rate in desired amounts. Many researchers have explored various nanotechnology-based approaches to provide effective and safe delivery of mangiferin for cancer therapy. Nanoparticles were used as carriers to encapsulate mangiferin, protecting it from degradation and facilitating its delivery to cancer cells. They have attempted to enhance the bioavailability, safety and efficacy of this very bioactive using drug delivery approaches. The present review focuses on the origin and structure elucidation of mangiferin and its derivatives and the benefits of this bioactive. The review also offers insight into the delivery-related challenges of mangiferin and its applications in nanosized forms against cancer. The use of a relatively new deep-learning approach to solve the pharmacokinetic issues of this bioactive has also been discussed. The review also critically analyzes the future hope for mangiferin as a therapeutic agent for cancer management.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15164194

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inconsistent reporting of dose-exposure relationships across preclinical studies complicates cross-study comparisons and dose selection for human studies.

    “iv) inconsistent reporting of dose-exposure relationships across preclinical studies (170,171). These issues complicate cross-study comparisons and dose selection for human studies.”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [170]

    Section 4, “Challenges in the Clinical Translation” (page unavailable), discusses mangiferin’s low bioavailability and solubility. Section 5 (page unavailable) says patent evaluations lack a standardized approach, but neither passage addresses inconsistent reporting of dose–exposure relationships across preclinical studies or its effect on cross-study comparisons and human dose selection. Searches for those terms found no passage making the attributed point. (LLM, conf=0.73)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 108 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [86]Chaurawal N. Raza K. Models Used for Pharmacokinetic Evaluation of Nanoparticulate Drug Delivery Systems (NPDDS) Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems Springer Cham, Switzerland 2022 53 67 10.1007/978-3-030-83395-4_4 · DOI

Cited by

Sorted by citations

Authors
Sarfraz, M., Khan, A., Batiha, G. E.-S., Akhtar, M. F., Saleem, A., Ajiboye, B. O., Kamal, M., Ali, A., Alotaibi, N. M., Aaghaz, S., Siddique, M. I., & Imran, M.
Affiliations
  • Al Ain University (AE)
  • Northern Border University (SA)
  • Damanhour University (EG)
  • Riphah International University (PK)
  • Department of Pharmacology, Faculty of Pharmaceutical Sciences, GC University Faisalabad, Faisalabad 38000, Pakistan
  • Federal University Oye Ekiti (NG)
  • Prince Sattam Bin Abdulaziz University (SA)
  • Taif University (SA)
  • Galgotias University (IN)
Corresponding author
  • Sarfraz, Muhammad
  • Imran, Mohd
Venue
Cancers
Publisher
MDPI AG
Published
2023-08-21
Volume
15
Issue
16
Pages
4194
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4386031769
Cited by
20
References
108
Citations by year
2026: 8 · 2025: 8 · 2024: 4
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Deanship of Scientific Research at Northern Border University, Arar, KSA (NBU-FFR-2023-0072)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
Keywords
mangiferin, xanthones, nanotechnology-based drug delivery, anticancer activity, breast cancer, oral bioavailability, water solubility, nanoparticles, pharmacokinetics, deep learning, nutraceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review